An organic CD4 inhibitor reduces the clinical and pathological symptoms of acute experimental allergic encephalomyelitis

Journal of Autoimmunity

Volumn 18, Issue 2, 2002, Pages 169-179

  Edling, Andrea E ^a   Choksi, Swati ^a   Huang, Ziwei ^a   Korngold, Robert ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Autoimmunity; CD4; EAE; T cells; Therapeutics

Indexed keywords

ANTIMITOTIC AGENT; CD4 ANTIGEN; CYTOKINE; N (3 INDOYLMETHYLENE)ISONICOTINIC HYDRAZONE; PROTEOLIPID; TJU 103; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CELL ACTIVATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; FEMALE; IMMUNOCOMPETENT CELL; MITOSIS INHIBITION; MOLECULE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0036525503     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1006/jaut.2001.0576     Document Type: Article

References (46)

1. Clark S.J., Jefferies W.A., Barclay A.N., Gagnon J., Williams A.F. Peptide and nucleotide sequences of rat CD4 (W3/25) antigen: evidence for derivation from a structure with four immunoglobulin-related domains. Proc. Natl. Acad. Sci. USA. 84:1987;1649-1653.
2. Maddon P.J., Littman D.R., Godfrey M., Maddon D.E., Chess L., Axel R. The isolation and nucleotide sequence of a cDNA encoding the T cell surface protein T4: a new member of the immunoglobulin gene family. Cell. 42:1985;93-104.
3. Cammarota G., Scheirle A., Takacs B., Doran D.M., Knorr R., Bannwarth W., Guardiola J., Sinigaglia F. Identification of a CD4 binding site on the beta 2 domain of HLA-DR molecules. Nature. 356:1992;799-801.
4. Veillette A., Bookman M.A., Horak E.M., Bolen J.B. The CD4 and CD8 T cell suface antigens are associated with the internal membrane tyrosine-protein kinase p56lck. Cell. 55:1988;301-308.
5. Owens T., Fazekas de St. Groth B.F., Miller J.F. Coaggregation of the T cell receptor with CD4 and other T cell surface molecules enhances T cell activation. Proc. Natl. Acad. Sci. USA. 84:1987;9209-9213.
6. Wang J., Yan Y.W., Garrett T.P., Liu J.H., Rodgers D.W., Garlick R.L., Tarr G.E., Husain Y., Reinherz E.L., Harrison S.C. Atomic structure of a fragment of human CD4 containing two immunoglobulin-like domains. Nature. 348:1990;411-418.
7. Fleury S., Lamarre D., Meloche S., Ryu S.E., Cantin C., Hendrickson W.A., Sekaly R.P. Mutational analysis of the interaction between CD4 and class II MHC: class II antigens contact CD4 on a surface opposite the gp120-binding site. Cell. 66:1991;1037-1049.
8. Sakihama T., Smolyar A., Reinherz E.L. Oligomerization of CD4 is required for stable binding to class II major histocompatibility complex protein but not for interaction with human immunodeficiency virus gp120. Proc. Natl. Acad. Sci. USA. 92:1995;6444-6448.
9. Konig R., Shen Y., Germain R.N. Involvement of both major histocompatibility complex class II and chains in CD4 function indicates a role for ordered oligomerization in T cell activation. J. Exp. Med. 182:1995;779-787.
10. Wu, H. Kwong, D. Hendrickson, W.A. 1997, Dimeric association and segmental variability in the structure of human CD4, Nature, 387, 527, 530.
11. Li S., Gao J., Satoh T., Friedman T.M., Edling A.E., Koch U., Choksi S., Han X., Korngold R., Huang Z. A computer screening approach to immunoglobulin superfamily structures and interactions: discovery of small non-peptidic CD4 inhibitor as novel immunotherapeutics. Proc. Natl. Acad. Sci. USA. 94:1997;73-78.
12. - T lymphocytes. J. Immunol. 127:1981;1420-1423.
13. Sriram S., Solomon D., Rouse R.V., Steinman L. Identification of T cell subsets and B lymphocytes in mouse brain EAE lesions. J. Immunol. 129:1982;1649-1651.
14. Traugott U., Reinherz E.L., Raine C.S. Multiple sclerosis: distribution of T cell subsets with active chronic lesions. Science. 219:1983;308-310.
15. Neurology. 43:1993;655-661.
16. Paty D.W., Li D.K. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis II: MRI analysis results of a multicenter, randomized, double-blinded, placebo-controlled trial. UBC MSI MRI Study Group: IFNB Multiple Sclerosis Study Group. Neurology. 43:1993;662-667.
17. Johnson K.P., Brooks B.R., Cohen J.A., Ford C.C., Goldstein J., Lisak R.P., Myers L.W., Panitch H.S., Rose J.W., Schiffer R.B. Copolymer 1 reduces rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology. 45:1995;1268-1276.
18. Cobbold S.P., Jayasuriya A., Nash A., Prospero T.D., Waldman H. Therapy with monoclonal antibodies by elimination of T cell subsets in vivo. Nature. 312:1984;548-551.
19. Waldor M.K., Sriram S., Hardy R., Herzenberg L.A., Herzenberg L.A., Lanier L., Lim M., Steinman L. Reversal of EAE with a monoclonal antibody to a T cell subset marker. Science. 227:1985;415-417.
20. Sriram S., Roberts C.A. Treatment of established chronic relapsing EAE with anti-L3T4 antibodies. J. Immunol. 136:1986;4464-4469.
21. + single positive cells with a class II major histocompatibility complex-restricted receptor. J. Exp. Med. 180:1994;25-34.
22. Pircher H., Burki K., Lang R., Hengartner H., Zinkernagel R.M. Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature. 342:1989;559-561.
23. Doyle C., Strominger J.L. Interaction between CD4 and class II MHC molecules mediates cell adhesion. Nature. 330:1987;256-259.
24. Tuohy V.K., Lu Z., Sobel R.A., Laursen R.A., Lees M.B. Identification of an encephalogenic determinant of myelin proteolipid protein for SJL mice. J. Immunol. 142:1989;1523-1527.
25. Korngold R., Feldman A., Rorke L.B., Lublin F.B., Doherty P.C. Acute experimental allergic encephalomyelitis in radiation bone marrow chimeras between high and low susceptible strains of mice. Immunogenetics. 24:1986;309-315.
26. Czerkinsky C., Andersson G., Ekre H., Nilsson L.A., Klareskog L., Ouchterlony O. Reverse ELISPOT assay for clinical analysis of cytokine production. J. Immunol. Methods. 110:1988;29.
27. Steinman L., Rosenbuan J.T., Sriram S., McDevitt H.O. In vivo effects of antibodies to immune response gene products: prevention of experimental allergic encephalitis. Proc. Natl. Acad. Sci. USA. 78:1981;7111-7114.
28. Sriram S., Steinman L. Anti-I-A antibody suppresses active encephalomyelitis: treatment model for diseases linked to IR genes. J. Exp. Med. 158:1983;1362-1367.
29. Rep M.H.G., van Oosten B.W., Roos M.T.L., Ader H.J., Polman C.H., van Lier R.A.W. Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-γ secreting TH1 cells in humans. J. Clin. Invest. 99:1997;2225-2231.
30. Hutchings P., O'Reilly L., Parish N.M., Waldmann H., Cooke A. The use of a non-depleting anti-CD4 monoclonal antibody to re-establish tolerance to beta cells in NOD mice. Eur. J. Immunol. 22:1992;1913-1918.
31. Biasi G., Facchinetti A., Monastra G., Mezzalira S., Sivieri S., Tavolato B., Gallo P. Protection from experimental autoimmune encephalomyelitis (EAE): non-depleting anti-CD4 mAb treatment induces peripheral T-cell tolerance to MBP in PL/J mice. J. Neuroimmunol. 73:1997;117-123.
32. Cobbold S.P., Martin G., Waldmann H. The induction of skin graft tolerance in major histocompatibility complex-mismatched or primed recipients: primed T cells can be tolerized in the periphery with anti-CD4 and anti-CD8 antibodies. Eur. J. Immunol. 20:1990;2747-2755.
33. Darby C.R., Morris P.J., Wood K.J. Evidence that long-term cardiac allograft survival induced by anti-CD4 monoclonal antibody does not require depletion of CD4+ T cells. Transplantation. 54:1992;483-490.
34. Chong A.S., Ma L., Yin D., Shen J., Blinder L., XiuLong X., Williams J.W., Byrne G., Diamond L.E., Logan J.S. Non-depleting anti-CD4, but not anti-CD8, antibody induces long-term survival of xenogeneic and allogeneic hearts in alpha1,3-galactosyltransferase knockout (GT-Ko) mice. Xenotransplantation. 7:2000;275-283.
35. Niimi M., Shirasugi N., Hamano K., Esato K., Matsumoto K., Ikeda Y., Shatari T., Takami H., Kodaira S. Oral delivery of xeno-antigen combined with non-depleting anti-CD4 monoclonal antibody induces significantly prolonged survival of concordant skin xenograft. Xenotransplantation. 8:2001;75-79.
36. Isaacs J.D., Burrows N., Wing M., Keogan M.T., Rebello P.R., Watts R.A., Pye R.J., Norris P., Hazelman B.L., Hale G., Waldmann H. Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease. Clin. Exp. Immunol. 110:1997;158-166.
37. Schulze-Koops H., Davis L.S., Haverty T.P., Wacholtz M.C., Lipsky P.E. Reduction of Th1 cell activity in the peripheral circulation of patients with rheumatoid arthritis after treatment with a non-depleting humanized monoclonal antibody to CD4. J. Rheumatol. 25:1998;2065-2076.
38. Marini J.C., Jameson B.A., Lublin F.D., Korngold R. A CD4-CDR3 peptide analog inhibits both primary and secondary autoreactive CD4 T cell responses in EAE. J. Immunol. 157:1996;3706-3715.
39. Edling A.E., Choksi S., Huang Z., Korngold R. Effect of a synthetic peptide mimic of the human CD4 domain 1 CC′-loop region on murine experimental allergic encephalomyelitis: Inhibition of both primary and secondary responses. J. Neuroimmunol. 112:2001;115-128.
40. Jacob S.W., Herschler R. Pharmacology of DMSO. Cryobiology. 23:1986;14-27.
41. Ridgway W., Fasso M., Fathman C.G. Following antigen challenge, T cells up-regulate cell surface expression of CD4 in vitro and in vivo. J. Immunol. 161:1998;714-720.
42. Vollmer T.L., Waldor M.K., Steinman L., Conley F.K. Depletion of T4+ lymphocytes with monoclonal antibody reactivates toxoplasmosis in the central nervous system: a model of superinfection in AIDS. J. Immunol. 138:1987;3737-3741.
43. Merrill J.E., Kono D.H., Clayton J., Ando D.G., Hinton R., Hofman F.M. Inflammatory leukocytes and cytokines in the peptide-induced disease of EAE in SJL and B10.PL mice. Proc. Natl. Acad. Sci. USA. 89:1992;574-578.
44. Kennedy M.K., Torrance D.S., Picha K.S., Mohler K.M. Analysis of cytokine mRNA expression in the central nervous sytem of mice with EAE reveals that IL-10 mRNA expression correlates with recovery. J. Immunol. 149:1992;2496-2505.
45. Langedijk J.P.M., Puijk W.C., Van Hoorn W.P., Meloen R.H. Location of CD4 dimerization site explains critical role of CDR3-like region in HIV-1 infection and T-cell activation and implies a model for complex of coreceptor-MHC. J. Biol. Chem. 268:1993;16875-16878.
46. Li S., Satoh T., Korngold R., Huang Z. CD4 dimerization and oligomerization: implications for T cell function and structure-based drug design. Immunol. Today. 19:1998;455-462.